Serena Silver was promoted to Chief Scientific Officer at Accent as of January 1, 2025. She joined Accent in 2022 as Vice President of Biology, bringing a breadth of experience across target discovery, drug discovery, and translational research. Prior to joining Accent, Serena was Vice President of Discovery Biology and Technologies at Fulcrum Therapeutics, where she led scientific teams to develop and deploy new assay modalities and complex cellular models of disease to identify targets and discover therapeutics for rare diseases. Previously, Serena led the Molecular Pharmacology group at Novartis Oncology, the Target ID & Validation team at Sanofi Oncology, and worked at the forefront of functional genomics screening technology at the Broad Institute. Dr. Silver holds a Ph.D. in Biology from the Massachusetts Institute of Technology and completed a postdoctoral fellowship at Harvard Medical School.